# US 8,569,374 B2 · NADPH oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,569,374 B2
- Document ID: US8569374B2
- Status: Granted
- Kind: B2
- Application number: 11/226,471
- Filed: 2005-09-15
- Published: 2006-07-13
- Granted: 2013-10-29
- Earliest claimed: 2004-09-16
- Assignees: The Trustees of the University of Pennsylvania
- Applicants: Sigrid C. Veasey
- Inventors: Sigrid C. Veasey
- Web page: https://patentgrep.com/patent/US8569374B2

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- C12Y 301/03002: Acid phosphatase (3.1.3.2)
- C12N 2310/14: interfering nucleic acids [NA]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

The invention relates to compositions and methods for treating Obstructive Sleep Apnea (OSA). Specifically, the invention relates to the use of NADPH Oxigenase inhibitors in compositions and methods for treating OSA in a subject.

## Claims

### Claim 1

A method for treating a hypersomnolence or sleepiness associated with Obstructive Sleep Apnea (OSA) hypopnea syndrome in a subject having OSA, comprising administering a therapeutically effective amount of a composition comprising an NADPH oxidase inhibitor to a subject in need thereof, wherein said method increases sleep latency in a healthy subject relative to a subject having OSA without impairing sleep loss-related sleepiness, thereby treating said hypersomnolence or sleepiness.

### Claim 2 (depends on 1)

The method of claim 1, wherein said NADPH oxidase inhibitor is apocynin.

### Claim 3

A method for treating a cardiovascular morbidity resulting from Obstructive Sleep Apnea (OSA) hypopnea syndrome, comprising administering a therapeutically effective amount of a composition comprising an NADPH oxidase inhibitor to a subject in need thereof, wherein said inhibitor reverses increases in proinflammatory gene expression in the cortex, hippocampus, and wake-active regions that result from OSA, thereby treating said cardiovascular morbidity.

### Claim 4 (depends on 1)

The method of claim 1, wherein said composition further comprises a siRNA targeted to p47phox subunit of NADPH oxidase.

### Claim 5 (depends on 1)

The method of claim 1, further comprising the step of coadministrering to said subject a COX-2 inhibitor.

### Claim 6 (depends on 1)

The method of claim 1, wherein said subject is a snorer.

### Claim 7 (depends on 3)

The method of claim 3, wherein said proinflammatory gene is tumor necrosis factor-alpha (TNF-α), Cyclooxygenase-2 (COX-2), or both.